High throughput screening in drug discovery.
High throughput screening in drug discovery.
复制标题
DOI：
10.1007/s12094-006-0048-2
复制
发表时间：
2006-07-01
期刊：
影响因子：
--
通讯作者：
Carnero, A
中科院分区：
文献类型：
--
作者：
Carnero, A
药物发现是一个高度复杂和多学科的过程，其目标是寻找新的抗肿瘤药物。目前药物发现方案中的筛选损失率表明，从大约100万个筛选的化合物中可以产生一种可上市的药物。这导致了为了继续流水线而筛选更大文库的压力，以及高通量筛选的发展。HTS只是实验室自动化在相对较短的时间内收集大量实验数据的具体发展的一个名称。HTS每天可以测试数十万种化合物，然而，如果能够在不影响成功概率的情况下测试更少的化合物，成本和时间将大大减少。为此，大规模细胞生物学和硅胶中化合物文库设计的新发展已经演变为获得具有更高临床疗效预测性的数据。
Drug discovery is a highly complex and multidisciplinary process which goal is to identify new antitumoral drugs. The screening attrition rate in the current drug discovery protocols suggests that one marketable drug emerges from approximately one million screened compounds. This leads to pressure to screen larger libraries in order to continue the pipeline and to the development of High Throughput Screening. HTS is only a name for specific developments in laboratory automation to collect a large amount of experimental data in a relatively short time. HTS can test hundreds of thousands of compounds per day, however, if fewer compounds could be tested without compromising the probability of success, the cost and time would be greatly reduced. To that end, new developments in large-scale cell biology and compound library design in silico have evolved to obtain data with higher predictability of clinical efficacy.